ARQT May 2024 10.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:07PM EDT. Market open.
| Previous close | 0.1000 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 10.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0300 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.5k |
- Thomson Reuters StreetEvents
Q1 2024 Arcutis Biotherapeutics Inc Earnings Call
Q1 2024 Arcutis Biotherapeutics Inc Earnings Call
- GuruFocus.com
Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
Explore key financial outcomes, product launches, and strategic initiatives as Arcutis Biotherapeutics navigates through a dynamic market landscape.
GlobeNewswireArcutis Announces First Quarter 2024 Financial Results and Provides Business Update
First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 60 percent rangeSustained growth in demand for cream and remarkable uptake of foam launched in JanuaryJuly 7, 2024 Prescription Drug User Fee Act (PDUFA) action date for roflumilast cream, 0.
© 2024 Yahoo. All rights reserved.